
Chemcon Speciality Chemicals Q3 FY21 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
No
Order
N/A
Capex
Yes
1 of 4 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Targeted growth of around 15% to 20% in HMDS volumes (Page 11).
- Around 30% growth expected in CMIC volumes, plus addition of new products (Page 11).
- Plan to increase production capacities and real-time production by 30% in FY2022 (Page 16).
- New products like 4-chlorobutyryl chloride and 2,5-DHT expected to contribute Rs. 75-100 Crores revenue each with less than 1-year capex payback period (Pages 12, 5-6).
- Expansion plants P8 and P9 to commercialize new and existing products, with P8 commercializing in ~5-5.5 months and P9 in ~12 months (Pages 5, 8).
- Bromide volumes expected to recover to 60-70% of earlier quarterly levels (~1 million kg) (Page 16).
- Focus on penetrating new clients, new geographic markets, and ongoing cost efficiencies as growth levers (Page 16).
- Innovation pipeline includes adding at least 2 new products annually (Page 12).
See what Chemcon Speciality Chemicals management said on margin guidance — free account, 30 seconds.
Fundraise plans
No- Chemcon Specialty Chemicals Limited has ongoing capital expenditure projects, specifically plants P8 and P9, funded by IPO proceeds and internal accruals.
- Rs. 25 Crores of capex has already been incurred, with further expenditure ongoing for these new plants.
- No explicit mention of any new or future fundraising through additional debt or equity beyond the IPO proceeds used for current expansions.
- The company is focusing on capacity expansions, new product commercialization, and increasing production volumes funded by internal resources and the IPO.
- No clear statement on plans for further capital raising was provided in the call.
See what Chemcon Speciality Chemicals management said on order book — free account, 30 seconds.
Capex plans
Yes- Ongoing capital expenditure on plants P8 and P9, funded partly by IPO proceeds and internal accruals; about Rs. 25 Crores incurred so far.
- P8 plant expected to be commercialized in approximately 5 to 5.5 months, and P9 plant around 12 months from the call date (Feb 2021).
- The new multipurpose plants (P8 & P9) will support existing products and enable manufacturing of new products such as 4-chlorobutyryl chloride, 2,5 DHT, and expanded CMIC capacity.
- Total volumetric reactor capacity after expansion will be ~625 kl.
- Future capex beyond P8 & P9 not specifically detailed but focus remains on continuous product additions and capacity expansions.
- New product additions target revenue sizes of Rs. 75-100 Crores with a payback period of under one year.
- Strategic emphasis on penetrating new clients, new geographic markets, and ongoing cost efficiencies to drive growth.
Track Chemcon Speciality Chemicals — get its next earnings analysis in your feed
How does Chemcon Speciality Chemicals rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Chemcon Speciality Chemicals rank in Chemicals & Petrochemicals?
Compare Chemcon Speciality Chemicals against every Chemicals & Petrochemicals company (Q3 FY21) on revenue, margins and earnings-call signals.
Continue your research
What Chemcon Speciality Chemicals's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…